Prognostic Value of Natural Killer Cell/T Cell Ratios for Disease Activity in Multiple Sclerosis

Overview

Journal Eur J Neurol

Publisher Wiley

Specialty Neurology

Date 2020 Dec 16

PMID 33326677

Citations 6

Authors

Max Mimpen

Anne-Hilde Muris

Linda Rolf

Oliver Gerlach

Jens Kuhle

Raymond Hupperts

Joost Smolders

Jan Damoiseaux

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Natural killer (NK) cells may play a role in multiple sclerosis (MS). Ratios of NK cells to CD4 T cells have been proposed as a biomarker for the therapeutic effect of stem cell transplantation in MS. The objectives here were to explore the relevance of this ratio in MS patients by analysing NK and T cell subsets, as well as their prognostic value for disease activity.

Methods: Baseline peripheral blood mononuclear cells of 50 relapsing-remitting MS patients, participating in our vitamin D supplementation study (SOLARIUM), were analysed with flow cytometry. Disease activity was measured as new magnetic resonance imaging lesions, relapses and mean plasma neurofilament light chain levels after 48 weeks of follow-up.

Results: The proportion of NK cells correlated negatively with CD4 T cells (R = -0.335, p = 0.001) and interleukin 17A (IL-17A ) CD4 T cells (R = -0.203, p = 0.043). Participants with magnetic resonance imaging activity or relapses displayed lower NK/IL-17A CD4 T cell ratios (p =0.025 and p = 0.006, respectively). The NK/IL-17A CD4 T cell ratio correlated negatively with neurofilament light chain levels (R = -0.320, p = 0.050). Vitamin D supplementation did not affect these ratios.

Conclusions: Our data suggest a protective role of an expanded NK cell compartment compared to the CD4 T cell subset fractions in relapsing-remitting MS patients. NK/CD4 T cell ratios may be a prognostic biomarker for disease activity in MS.

Citing Articles

The ratio of circulating CD56 NK cells to follicular T helper cells as a promising predictor for disease activity of relapsing-remitting multiple sclerosis.

Ding J, Yan X, Zhao C, Zhao D, Jia Y, Ren K Heliyon. 2024; 10(10):e31533.

PMID: 38803865 PMC: 11128518. DOI: 10.1016/j.heliyon.2024.e31533.

Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS.

Zrzavy T, Rieder K, Wuketich V, Thalhammer R, Haslacher H, Altmann P Front Neurol. 2024; 15:1388941.

PMID: 38689880 PMC: 11058637. DOI: 10.3389/fneur.2024.1388941.

Analysis of Novel Immunological Biomarkers Related to Rheumatoid Arthritis Disease Severity.

Pascual-Garcia S, Martinez-Peinado P, Lopez-Jaen A, Navarro-Blasco F, Montoyo-Pujol Y, Roche E Int J Mol Sci. 2023; 24(15).

PMID: 37569732 PMC: 10418816. DOI: 10.3390/ijms241512351.

Natural Killer Cells in Multiple Sclerosis: Entering the Stage.

Belien J, Goris A, Matthys P Front Immunol. 2022; 13:869447.

PMID: 35464427 PMC: 9019710. DOI: 10.3389/fimmu.2022.869447.

The IL-2 - IL-2 receptor pathway: Key to understanding multiple sclerosis.

Peerlings D, Mimpen M, Damoiseaux J J Transl Autoimmun. 2022; 4:100123.

PMID: 35005590 PMC: 8716671. DOI: 10.1016/j.jtauto.2021.100123.

References

Smolders J, Thewissen M, Peelen E, Menheere P, Cohen Tervaert J, Damoiseaux J . Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One. 2009; 4(8):e6635. PMC: 2721656. DOI: 10.1371/journal.pone.0006635. View

Muris A, Smolders J, Rolf L, Thewissen M, Hupperts R, Damoiseaux J . Immune regulatory effects of high dose vitamin D supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNβ; the SOLARIUM study. J Neuroimmunol. 2016; 300:47-56. DOI: 10.1016/j.jneuroim.2016.09.018. View

Nielsen N, Odum N, Urso B, Lanier L, Spee P . Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A. PLoS One. 2012; 7(2):e31959. PMC: 3284517. DOI: 10.1371/journal.pone.0031959. View

Simpson Jr S, Taylor B, Blizzard L, Ponsonby A, Pittas F, Tremlett H . Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010; 68(2):193-203. DOI: 10.1002/ana.22043. View

Kuhle J, Kropshofer H, Haering D, Kundu U, Meinert R, Barro C . Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019; 92(10):e1007-e1015. PMC: 6442011. DOI: 10.1212/WNL.0000000000007032. View

Liu Q, Sanai N, Jin W, La Cava A, Van Kaer L, Shi F . Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat Neurosci. 2016; 19(2):243-52. PMC: 5336309. DOI: 10.1038/nn.4211. View

Bielekova B, Richert N, Herman M, Ohayon J, Waldmann T, McFarland H . Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology. 2011; 77(21):1877-86. PMC: 3246406. DOI: 10.1212/WNL.0b013e318239f7ef. View

. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019; 365(6460). PMC: 7241648. DOI: 10.1126/science.aav7188. View

Jiang W, Chai N, Maric D, Bielekova B . Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol. 2011; 187(2):781-90. PMC: 3131478. DOI: 10.4049/jimmunol.1100789. View

10.

Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann T . Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A. 2006; 103(15):5941-6. PMC: 1458677. DOI: 10.1073/pnas.0601335103. View

11.

Hu D, Notarbartolo S, Croonenborghs T, Patel B, Cialic R, Yang T . Transcriptional signature of human pro-inflammatory T17 cells identifies reduced IL10 gene expression in multiple sclerosis. Nat Commun. 2017; 8(1):1600. PMC: 5693957. DOI: 10.1038/s41467-017-01571-8. View

12.

Salou M, Nicol B, Garcia A, Laplaud D . Involvement of CD8(+) T Cells in Multiple Sclerosis. Front Immunol. 2015; 6:604. PMC: 4659893. DOI: 10.3389/fimmu.2015.00604. View

13.

Machado-Santos J, Saji E, Troscher A, Paunovic M, Liblau R, Gabriely G . The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain. 2018; 141(7):2066-2082. PMC: 6022681. DOI: 10.1093/brain/awy151. View

14.

Gutcher I, Becher B . APC-derived cytokines and T cell polarization in autoimmune inflammation. J Clin Invest. 2007; 117(5):1119-27. PMC: 1857272. DOI: 10.1172/JCI31720. View

15.

Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P . T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 2009; 65(5):499-509. DOI: 10.1002/ana.21652. View

16.

Dobson R, Giovannoni G . Multiple sclerosis - a review. Eur J Neurol. 2018; 26(1):27-40. DOI: 10.1111/ene.13819. View

17.

Lu L, Ikizawa K, Hu D, Werneck M, Wucherpfennig K, Cantor H . Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. Immunity. 2007; 26(5):593-604. PMC: 3428267. DOI: 10.1016/j.immuni.2007.03.017. View

18.

Mimpen M, Smolders J, Hupperts R, Damoiseaux J . Natural killer cells in multiple sclerosis: A review. Immunol Lett. 2020; 222:1-11. DOI: 10.1016/j.imlet.2020.02.012. View

19.

Smolders J, Mimpen M, Oechtering J, Damoiseaux J, Van den Ouweland J, Hupperts R . Vitamin D supplementation and neurofilament light chain in multiple sclerosis. Acta Neurol Scand. 2019; 141(1):77-80. DOI: 10.1111/ane.13185. View

20.

Park H, Li Z, Yang X, Chang S, Nurieva R, Wang Y . A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005; 6(11):1133-41. PMC: 1618871. DOI: 10.1038/ni1261. View